市場調査レポート
商品コード
1173611

季節性インフルエンザ - 市場考察、疫学、市場予測(2032年)

Seasonal Influenza - Market Insights, Epidemiology, and Market Forecast-2032

出版日: | 発行: DelveInsight | ページ情報: 英文 379 Pages | 納期: 1~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.66円
季節性インフルエンザ - 市場考察、疫学、市場予測(2032年)
出版日: 2022年10月01日
発行: DelveInsight
ページ情報: 英文 379 Pages
納期: 1~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)の季節性インフルエンザの市場規模は、2021年に66億4,600万米ドルでした。

当レポートでは、季節性インフルエンザの主要7市場について調査分析し、市場規模と予測、現在の治療法と新薬の情報などを提供しています。

目次

第1章 主要考察

第2章 レポートのイントロダクション

第3章 季節性インフルエンザ市場の概要

  • 季節性インフルエンザの市場シェア分布(2019年)
  • 季節性インフルエンザの市場シェア分布(2032年)

第4章 季節性インフルエンザ市場:将来の見通し

第5章 季節性インフルエンザのエグゼクティブサマリー

第6章 主な出来事

第7章 疾患の背景と概要:季節性インフルエンザ

  • イントロダクション
  • 構造インフルエンザウイルス
  • インフルエンザウイルスのタイプ
  • インフルエンザA型の主な評価項目
  • 種間伝染
  • 原因
  • インフルエンザに関連する臨床症状と合併症
  • 病態生理学
  • 診断
  • 季節性インフルエンザの治療と管理

第8章 疫学と患者数

  • 主な調査結果
  • 疫学の調査手法
  • 前提条件と根拠:主要7市場
  • 主要7市場の季節性インフルエンザに関連する総通院数
  • 主要7市場の季節性インフルエンザの総入院患者数
  • 米国
  • 欧州の主要5カ国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本

第9章 ペイシェントジャーニー

第10章 上市済み薬品

第11章 上市済みワクチン

第12章 比較分析

  • 総製品数:段階別
  • 治療評価:有効な製品

第13章 新たな治療法

第14章 新たなワクチンと予防薬

第15章 季節性インフルエンザ:主要7市場の分析

  • 主な調査結果
  • 市場調査手法
  • 市場の見通し
  • 新たな治療法の可能性
  • 主な市場の予測の前提条件
  • 主要7市場の季節性インフルエンザの市場規模
  • 主要7市場の季節性インフルエンザの市場規模:製品別(治療・予防)
  • 米国の市場規模
  • 欧州の主要5市場の季節性インフルエンザの市場規模
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本の市場規模

第16章 主なオピニオンリーダーの見解

第17章 市場促進要因

第18章 市場障壁

第19章 アンメットニーズ

第20章 SWOT分析

第21章 市場参入と償還

第22章 付録

第23章 DelveInsightのサービス内容

第24章 免責事項

第25章 DelveInsightについて

図表

List of Tables

  • Table 1: Summary of Seasonal Influenza (2019-2032)
  • Table 2: Key Events
  • Table 3: Seasonal Influenza vs. Pandemic Flu
  • Table 4: Clinical Manifestations and Complications Associated With Influenza
  • Table 5: Advantages and disadvantages of influenza diagnostic tests
  • Table 6: Influenza Virus Testing Methods
  • Table 7: Influenza Treatment Recommendations
  • Table 8: Infectious Diseases Society of America - The US Public Health Service Grading System for Ranking Recommendations in Clinical Guidelines
  • Table 9: Total Medical Visits Related to Seasonal Influenza in the 7MM, in '000's (2019-2032)
  • Table 10: Total Hospitalized Cases of Seasonal Influenza in the 7MM (2019-2032)
  • Table 11: Total Medical visits related to Seasonal Influenza in the United States, '000's (2019-2032)
  • Table 12: Total Hospitalized Cases of Seasonal Influenza in the US (2019-2032)
  • Table 13: Type-specific Cases of Seasonal Influenza in the US (2019-2032)
  • Table 14: Influenza Vaccination Coverage of Seasonal Influenza in the US, in '000's (2019-2032)
  • Table 15: Total Medical visits related to Seasonal Influenza in the EU-5, '000's (2019-2032)
  • Table 16: Total Medical visits related to Seasonal Influenza in Germany (2019-2032)
  • Table 17: Total Medical visits related to Seasonal Influenza in France (2019-2032)
  • Table 18: Total Medical visits related to Seasonal Influenza in Italy (2019-2032)
  • Table 19: Total Medical visits related to Seasonal Influenza in Spain (2019-2032)
  • Table 20: Total Medical visits related to Seasonal Influenza in the UK (2019-2032)
  • Table 21: Total Hospitalized Cases of Seasonal Influenza in the EU-5 (2019-2032)
  • Table 22: Total Hospitalized Cases of Seasonal Influenza in Germany (2019-2032)
  • Table 23: Total Hospitalized Cases of Seasonal Influenza in France (2019-2032)
  • Table 24: Total Hospitalized Cases of Seasonal Influenza in Italy (2019-2032)
  • Table 25: Total Hospitalized Cases of Seasonal Influenza in Spain(2019-2032)
  • Table 26: Total Hospitalized Cases of Seasonal Influenza in the UK (2019-2032)
  • Table 27: Type-specific Cases of Seasonal Influenza in the EU-5 (2019-2032)
  • Table 28: Type-specific Cases of Seasonal Influenza in Germany (2019-2032)
  • Table 29: Type-specific Cases of Seasonal Influenza in France (2019-2032)
  • Table 30: Type-specific Cases of Seasonal Influenza in Italy (2019-2032)
  • Table 31: Type-specific Cases of Seasonal Influenza in Spain (2019-2032)
  • Table 32: Type-specific Cases of Seasonal Influenza in the UK (2019-2032)
  • Table 33: Influenza Vaccination Coverage of Seasonal Influenza in Germany, in '000's (2019-2032)
  • Table 34: Influenza Vaccination Coverage of Seasonal Influenza in France, in '000's (2019-2032)
  • Table 35: Influenza Vaccination Coverage of Seasonal Influenza in Italy, in '000's (2019-2032)
  • Table 36: Influenza Vaccination Coverage of Seasonal Influenza in Spain, in '000's (2019-2032)
  • Table 37: Influenza Vaccination Coverage of Seasonal Influenza in the UK, in '000's (2019-2032)
  • Table 38: Influenza Vaccination Coverage of Seasonal Influenza in the EU-5, in '000's (2019-2032)
  • Table 39: Total Medical visits related to Seasonal Influenza in Japan, in '000's (2019-2032)
  • Table 40: Total Hospitalized Cases of Seasonal Influenza in Japan (2019-2032)
  • Table 41: Type-specific Cases of Seasonal Influenza in Japan (2019-2032)
  • Table 42: Influenza Vaccination Coverage of Seasonal Influenza in Japan, in '000's (2019-2032)
  • Table 43: XOFLUZA (baloxavir marboxil), Clinical Trial Description, 2022
  • Table 44: RAPIVAB (peramivir injection), Clinical Trial Description, 2022
  • Table 45: FLUZONE QUADRIVALENT, Clinical Trial Description, 2022
  • Table 46: Percentage of Solicited Injection-site and Systemic Adverse Reactions Within 7 days After Vaccination in Children 6-35 months (Safety Analysis Set)b
  • Table 47: Percentage of Solicited Injection-site and Systemic Adverse Reactions Within 3 days After Vaccination in Adults 18 years and Older (Safety Analysis Set)b
  • Table 48: Percentage of Solicited Injection-site and Systemic Adverse Reactions Within 7 Days After Vaccination in Adults 65 Years of Age and Older (Safety Analysis Set)b
  • Table 49: FLUZONE High-dose Quadrivalent, Clinical Trial Description, 2022
  • Table 50: FLUBLOK QUADRIVALENT, Clinical Trial Description, 2022
  • Table 51: AFLURIA QUADRIVALENT, Clinical Trial Description, 2022
  • Table 52: FLUMIST QUADRIVALENT, Clinical Trial Description, 2022
  • Table 53: FLUCELVAX QUADRIVALENT, Clinical Trial Description, 2022
  • Table 54: AFLURIA QUADRIVALENT, Clinical Trial Description, 2022
  • Table 55: FLUARIX QUADRIVALENT, Clinical Trial Description, 2022
  • Table 56: FLULAVAL QUADRIVALENT, Clinical Trial Description, 2022
  • Table 57: FLUARIX QUADRIVALENT, Clinical Trial Description, 2022
  • Table 58: Total Products by Phase
  • Table 59: Assessment by Molecule Type
  • Table 60: Assessment by Route of Administration
  • Table 61: Comparison of emerging drugs under development
  • Table 62: SAB-176, Clinical Trial Description, 2022
  • Table 63: Neumifil, Clinical Trial Description, 2022
  • Table 64: ALVR106, Clinical Trial Description, 2022
  • Table 65: CC-42344, Clinical Trial Description, 2022
  • Table 66: Comparison of emerging vaccines and Prophylactic Agents under development
  • Table 67: mRNA-1010, Clinical Trial Description, 2022
  • Table 68: NanoFlu, Clinical Trial Description, 2022
  • Table 69: QVLP, Clinical Trial Description, 2022
  • Table 70: aQIV, Clinical Trial Description, 2022
  • Table 71: VXA-A1.1, Clinical Trial Description, 2022
  • Table 72: FLU-v, Clinical Trial Description, 2022
  • Table 73: VIS410, Clinical Trial Description, 2022
  • Table 74: INNA-051, Clinical Trial Description, 2022
  • Table 75: Neumifil, Clinical Trial Description, 2022
  • Table 76: CD388, Clinical Trial Description, 2022
  • Table 77: mRNA-1030 , Clinical Trial Description, 2022
  • Table 78: Adjuvanted Seasonal Recombinant QVLP Influenza Vaccine, Clinical Trial Description, 2022
  • Table 79: SP0273, Clinical Trial Description, 2022
  • Table 80: UniFlu, Clinical Trial Description, 2022
  • Table 81: GSK 4382276A, Clinical Trial Description, 2022
  • Table 82: CVSQIV, Clinical Trial Description, 2022
  • Table 83: CodaVax, Clinical Trial Description, 2022
  • Table 84: Key Market Forecast Assumptions for VXA-A1.1
  • Table 85: Key Market Forecast Assumptions for mRNA-1010
  • Table 86: Key Market Forecast Assumptions for QVLP
  • Table 87: Key Market Forecast Assumptions for NanoFlu
  • Table 88: Key Market Forecast Assumptions for FLU-v
  • Table 89: Key Market Forecast Assumptions for SAB-176
  • Table 90: Market Size of Seasonal Influenza in the 7MM, in USD million (2019-2032)
  • Table 91: Market Size of Seasonal Influenza in the 7MM by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 92: The Market Size of Seasonal Influenza in the US, in USD million (2019-2032)
  • Table 93: Market Size of Seasonal Influenza in the US by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 94: Market Size of Seasonal Influenza in the EU-5, in USD million (2019-2032)
  • Table 95: Market Size of Seasonal Influenza in Germany, in USD million (2019-2032)
  • Table 96: Market Size of Seasonal Influenza in France, in USD million (2019-2032)
  • Table 97: Market Size of Seasonal Influenza in Italy, in USD million (2019-2032)
  • Table 98: Market Size of Seasonal Influenza in Spain, in USD million (2019-2032)
  • Table 99: Market Size of Seasonal Influenza in the UK, in USD million (2019-2032)
  • Table 100: Market Size of Seasonal Influenza in the EU-5 by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 101: Market Size of Seasonal Influenza in Germany by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 102: Market Size of Seasonal Influenza in France by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 103: Market Size of Seasonal Influenza in Italy by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 104: Market Size of Seasonal Influenza in Spain by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 105: Market Size of Seasonal Influenza in the UK by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 106: The Market Size of Seasonal Influenza in Japan, in USD million (2019-2032)
  • Table 107: Market Size of Seasonal Influenza in Japan by products (treatment and prophylaxis), in USD million (2019-2032)
  • Table 108: Overview of How Vaccine Prices are Set
  • Table 109: Medicare Payment Allowances and Effective Dates for the 2022-2023 Flu Season
  • Table 110: Influenza Billing Codes for Medicaid Beneficiaries Less Than 19 years who Receive VFC Influenza Vaccine
  • Table 111: CPT Code(s) for Claims Processing
  • Table 112: Influenza Vaccine Purchased and Administered to Beneficiaries 19-21 years
  • Table 113: Administrative CPT Codes to Report
  • Table 114: Codes to Bill Medicaid for Influenza Vaccine Purchased and Administered to Beneficiaries 21 years and Older
  • Table 115: Administrative CPT Code(s) to Bill
  • Table 116: Reimbursed Vaccines as Part of the NHS Seasonal Influenza Vaccination Program 2022/2023

List of Figures

  • Figure 1: Clinical representation of seasonal influenza
  • Figure 2: Structure-Influenza virus
  • Figure 3: Human Seasonal Influenza Virus
  • Figure 4: Symptoms of Influenza
  • Figure 5: Symptoms and complications of influenza
  • Figure 6: Antigenic drift and antigenic shift.
  • Figure 7: Influenza antigenic shift and antigenic drift.
  • Figure 8: Standard Assessment Protocol in
  • Figure 9: Guide to use of influenza virus diagnostic tests in investigating outbreaks in institutional or other closed settings
  • Figure 10: Algorithm to assist in the interpretation of influenza testing results and clinical decision-making during periods when influenza viruses are circulating in the community
  • Figure 11: Algorithm to assist in the interpretation of influenza testing results and clinical decision-making during periods when influenza viruses are NOT circulating in the community
  • Figure 12: Antiviral Drug Classification
  • Figure 13: Suggested Treatment Algorithm for Seasonal Influenza Patients
  • Figure 14: Total Medical Visits Related to Seasonal Influenza in the 7MM (2019-2032)
  • Figure 15: Total Hospitalized Cases of Seasonal Influenza in the 7MM (2019-2032)
  • Figure 16: Total Medical visits related to Seasonal Influenza in the United States (2019-2032)
  • Figure 17: Total Hospitalized Cases of Seasonal Influenza in the US (2019-2032)
  • Figure 18: Type-specific Cases of Seasonal Influenza in the US (2019-2032)
  • Figure 19: Influenza Vaccination Coverage of Seasonal Influenza in the US (2019-2032)
  • Figure 20: Total Medical visits related to Seasonal Influenza in the EU-5 (2019-2032)
  • Figure 21: Total Medical visits related to Seasonal Influenza in Germany (2019-2032)
  • Figure 22: Total Medical visits related to Seasonal Influenza in France (2019-2032)
  • Figure 23: Total Medical visits related to Seasonal Influenza in Italy (2019-2032)
  • Figure 24: Total Medical visits related to Seasonal Influenza in Spain (2019-2032)
  • Figure 25: Total Medical visits related to Seasonal Influenza in the UK (2019-2032)
  • Figure 26: Total Hospitalized Cases of Seasonal Influenza in the EU-5 (2019-2032)
  • Figure 27: Total Hospitalized Cases of Seasonal Influenza in Germany (2019-2032)
  • Figure 28: Total Hospitalized Cases of Seasonal Influenza in France (2019-2032)
  • Figure 29: Total Hospitalized Cases of Seasonal Influenza in Italy (2019-2032)
  • Figure 30: Total Hospitalized Cases of Seasonal Influenza in Spain(2019-2032)
  • Figure 31: Total Hospitalized Cases of Seasonal Influenza in the UK (2019-2032)
  • Figure 32: Type-specific Cases of Seasonal Influenza in the EU-5 (2019-2032)
  • Figure 33: Type-specific Cases of Seasonal Influenza in Germany (2019-2032)
  • Figure 34: Type-specific Cases of Seasonal Influenza in France (2019-2032)
  • Figure 35: Type-specific Cases of Seasonal Influenza in Italy (2019-2032)
  • Figure 36: Type-specific Cases of Seasonal Influenza in Spain (2019-2032)
  • Figure 37: Type-specific Cases of Seasonal Influenza in the UK (2019-2032)
  • Figure 38: Influenza Vaccination Coverage of Seasonal Influenza in Germany, in '000's (2019-2032)
  • Figure 39: Influenza Vaccination Coverage of Seasonal Influenza in France, in '000's (2019-2032)
  • Figure 40: Influenza Vaccination Coverage of Seasonal Influenza in Italy, in '000's (2019-2032)
  • Figure 41: Influenza Vaccination Coverage of Seasonal Influenza in Spain, in '000's (2019-2032)
  • Figure 42: Influenza Vaccination Coverage of Seasonal Influenza in the UK, in '000's (2019-2032)
  • Figure 43: Influenza Vaccination Coverage of Seasonal Influenza in the EU-5 (2019-2032)
  • Figure 44: Total Medical visits related to Seasonal Influenza in Japan (2019-2032)
  • Figure 45: Total Hospitalized Cases of Seasonal Influenza in Japan (2019-2032)
  • Figure 46: Type-specific Cases of Seasonal Influenza in Japan (2019-2032)
  • Figure 47: Influenza Vaccination Coverage of Seasonal Influenza in Japan (2019-2032)
  • Figure 48: Patient Journey of Seasonal Influenza
  • Figure 49: Total Products by Phase
  • Figure 50: Assessment by Molecule Type
  • Figure 51: Assessment by Stage and Molecule Type
  • Figure 52: Assessment by Route of Administration
  • Figure 53: Assessment by Stage and ROA
  • Figure 54: Market Size of Seasonal Influenza in the 7MM, in USD million (2019-2032)
  • Figure 55: Market Size of Seasonal Influenza by products (treatment and prophylaxis) in the 7MM, in USD million (2019-2032)
  • Figure 56: Market Size of Seasonal Influenza in the US, in USD million (2019-2032)
  • Figure 57: Market Size of Seasonal Influenza by products (treatment and prophylaxis) in the United States, in USD million (2019-2032)
  • Figure 58: Market Size of Seasonal Influenza in the EU-5, in USD million (2019-2032)
  • Figure 59: Market Size of Seasonal Influenza in Germany, in USD million (2019-2032)
  • Figure 60: Market Size of Seasonal Influenza in France, in USD million (2019-2032)
  • Figure 61: Market Size of Seasonal Influenza in Italy, in USD million (2019-2032)
  • Figure 62: Market Size of Seasonal Influenza in Spain, in USD million (2019-2032)
  • Figure 63: Market Size of Seasonal Influenza in the UK, in USD million (2019-2032)
  • Figure 64: Market Size of Seasonal Influenza by products (treatment and prophylaxis), in the EU-5, in USD million (2019-2032)
  • Figure 65: Market Size of Seasonal Influenza in Germany by products (treatment and prophylaxis), in USD million (2019-2032)
  • Figure 66: Market Size of Seasonal Influenza in France by products (treatment and prophylaxis), in USD million (2019-2032)
  • Figure 67: Market Size of Seasonal Influenza in Italy by products (treatment and prophylaxis), in USD million (2019-2032)
  • Figure 68: Market Size of Seasonal Influenza in Spain by products (treatment and prophylaxis), in USD million (2019-2032)
  • Figure 69: Market Size of Seasonal Influenza in the UK by products (treatment and prophylaxis), in USD million (2019-2032)
  • Figure 70: Market Size of Seasonal Influenza in Japan, in USD million (2019-2032)
  • Figure 71: Market Size of Seasonal Influenza by products (treatment and prophylaxis) in Japan, in USD million (2019-2032)
  • Figure 72: Market Drivers
  • Figure 73: Market Barriers
  • Figure 74: Unmet Needs
  • Figure 75: SWOT Analysis
目次
Product Code: DIMI1710

DelveInsight's 'Seasonal Influenza - Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the Seasonal Influenza, historical and forecasted epidemiology as well as the Seasonal Influenza market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Seasonal Influenza market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM Seasonal Influenza market size from 2019 to 2032. The Report also covers current Seasonal Influenza treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032.

Seasonal Influenza- Disease Understanding and Treatment Algorithm

Seasonal influenza is an acute viral infection that spreads easily from person to person, causing annual epidemics which peak during the winter in temperate regions of the world. There are four types of influenza viruses: influenza A, B, C, and D, but only influenza A and B viruses cause clinically important human diseases and seasonal epidemics.

Seasonal influenza is caused by a novel variant that exhibits antigenicity that is distinct from the past strains due to accumulated mutations. While seasonal influenza (flu) viruses are detected year-round in the United States, flu viruses are most common during the fall and winter. Initially, nonspecific symptoms predominate, including fever, chills or frank shaking, headaches, myalgia (muscle pain), malaise (discomfort), and anorexia.

Seasonal Influenza Diagnosis

A diagnosis of influenza is made mostly on the basis of clinical presentation and epidemiological likelihood of infection. As influenza-like illness can be caused by many viruses, the gold standard laboratory tests used for influenza are viral culture and reverse transcription PCR (RT-PCR).

Continued in the report…..

Seasonal Influenza Treatment

Influenza occurs in outbreaks and epidemics worldwide, mainly during the winter season. Influenza is usually a self-limited infection; however, it is associated with increased morbidity and mortality in certain high-risk patient groups. Some treatments can help relieve common flu symptoms such as fever, aches, and cough and may shorten the time of flu symptoms.

Many people with uncomplicated influenza use over-the-counter medicines, get rest and take plenty of fluids to lessen their symptoms.

The FDA has approved several drugs for the treatment and prevention of influenza. Yearly vaccination is the primary means of preventing and controlling influenza. Antiviral drugs can reduce the time it takes for symptoms to improve. Some are also used in selected situations to reduce the chance of illness in people exposed to influenza virus.

Continued in the report…..

Seasonal Influenza Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Medical visits related to Seasonal Influenza, Total Hospitalized Cases of Seasonal Influenza, Type-specific Cases of Seasonal Influenza, and Influenza Vaccination Coverage in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Key Findings

  • In the assessment done by DelveInsight, the estimated total medical visits related to seasonal influenza in the 7MM were 11,235,325 in 2021.
  • The highest total medical visits related to Seasonal Influenza were accounted by the US in 2021 (4,314,281 cases), which are expected to show a rise in the future.
  • In the EU-5, in 2021, Italy had the highest medical visits related to seasonal influenza with 2,937,446 cases, followed by France with 1,977,533 cases in the same year. On the other hand, Spain had the lowest medical visits of seasonal influenza as 228,686 cases in 2021.
  • In 2021, the total hospitalized cases of seasonal influenza was 173,227 in 7MM which are expected to increase by 2032.
  • Type-specific cases of seasonal influenza were categorized into two types, Type A and Type B. The United States showed the highest cases of Type A compared to other 7MM countries. In 2021, the US, alone accounts for approximately 60% of total cases of Type A influenza.
  • In 2021, the total vaccinated population estimated to be 366,474,828 in the 7MM. Highest vaccinated population was seen in the US.
  • In Japan, 8,105 medical visits related to seasonal influenza were estimated in 2021, which are expected to decline during the forecasted period (2022-2032).
  • During the peak year of COVID-19 pandemic, a steep decline in the cases of seasonal influenza was recorded throughout the 7MM. These cases are anticipated to rise again during the forecasted period (2022-2032).

Seasonal Influenza Epidemiology

The epidemiology segment also provides the Seasonal Influenza epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Seasonal Influenza Drug Chapters

The drug chapter segment of the Seasonal Influenza report encloses the detailed analysis of Seasonal Influenza drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Seasonal Influenza clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.

Seasonal Influenza Marketed Therapies

XOFLUZA (baloxavir marboxil): Genentech/Roche

XOFLUZA is a first-in-class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies.

Seasonal Influenza Marketed Vaccine

FLUZONE QUADRIVALENT /VAXIGRIP TETRA: Sanofi

FLUZONE QUADRIVALENT is a quadrivalent inactivated influenza vaccine produced in the US, containing two Type A antigens and two Type B antigens to provide increased protection against more circulating strains of influenza viruses.

Products detail in the report…

List to be continued in the report…

Seasonal Influenza Emerging Therapies

SAB-176: SAb Biotherapeutics, Inc.

SAB-176 is a multivalent, broadly neutralizing fully human polyclonal antibody therapeutic candidate developed by SAb Biotherapeutics that leverages the human biological immune response in developing the treatment of hospitalized patients with severe seasonal influenza.

Seasonal Influenza Emerging Vaccines

mRNA-1010: ModernaTX, Inc.

mRNA-1010 is Moderna's first seasonal influenza mRNA vaccine candidate to enter the clinic. The mRNA-1010 is a quadrivalent vaccine candidate that encodes for hemagglutinin glycoproteins of the four influenza strains recommended by the WHO for the prevention of influenza, including influenza A/H1N1, A/H3N2, and Influenza B/Yamagata- and B/Victoria-lineages.is Moderna's first seasonal influenza mRNA vaccine candidate to enter the clinic.

Products detail in the report…

List to be continued in the report…

Seasonal Influenza Market Outlook

Seasonal Influenza spreads through respiratory droplets and is very contagious, and most people can receive at-home care for the flu. Symptom relief may be achieved by combining lifestyle changes with over-the-counter medications. Patients not from a high-risk group can be managed with symptomatic treatment whereas, patients with severe or progressive clinical illness associated with suspected or confirmed influenza virus infection (i.e., clinical syndromes of pneumonia, sepsis, or exacerbation of chronic underlying diseases) can be treated with the antiviral drug. Prophylactic treatment is part of the treatment for influenza.

Antiviral medicines play a vital role in controlling influenza by treating the patient's infection and helping to prevent severe illnesses resulting from flu, including bacterial pneumonia. Several antiviral drugs are available to target the influenza virus, such as oseltamivir (TAMIFLU), zanamivir (RELENZA), peramivir (RAPIVAB), and some others.

The best way to reduce the risk of seasonal influenza and its potentially serious complications is to get vaccinated every year. Vaccination of people at higher risk of developing serious flu complications is essential to decrease their risk of severe flu illness.

Continued in the report…..

Key Findings

  • The therapeutic market size of Seasonal Influenza in the 7MM was USD 6,646 million in 2021.
  • Among all seven major markets, the US consistently captured the highest market with USD 3,999 million in 2021, which might grow by 2032.
  • Among the EU5 countries, Germany being the player captured total market share of USD 523 million followed by France, Italy, the UK and Spain in 2021.
  • Among 7MM, Japan represented approximately 12% of the total market of seasonal flu in 2021, which is expected to increase by 2032.
  • Several companies are trying their hand in the developmental pipeline of seasonal influenza to address some unmet needs and gain bundles of market opportunities. The pipeline projects are focused on the prevention and treatment of the flu.
  • The entry of mid and late-phase potential molecules like mRNA-1010 (ModernaTX, Inc.), Quadrivalent VLP vaccine (Medicago), NanoFlu (Novavax), SAB-176 (SAb Biotherapeutics) and some others, covering a broad spectrum of seasonal influenza may bring revolution in the prevention and treatment by 2032.

The United States Market Outlook

This section provides the total Seasonal Influenza market size and market size by therapies in the United States.

EU-5 Market Outlook

The total Seasonal Influenza market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Seasonal Influenza market size and market size by therapies in Japan are provided.

Seasonal Influenza Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the Seasonal Influenza or expected to get launched in the market during the study period 2019-2032. The analysis covers Seasonal Influenza market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Seasonal Influenza Development Activities

The report provides insights into different therapeutic candidates in the Early Phase, Phase II, and Phase III stages. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Seasonal Influenza emerging therapies.

Reimbursement Scenario in Seasonal Influenza

Reimbursement is a crucial factor affecting the drug's market access. The NC Immunization Program/Vaccines for Children (NCIP/VFC) offers vaccines at no cost for eligible children through VFC-enrolled doctors. TRICARE program covers age-appropriate doses of vaccines, as recommended by CDC, and it regularly adds coverage for new vaccines based on CDC recommendations. The Medicare Part B payment allowance limits for seasonal influenza (flu) vaccines are 95% of the average wholesale price (AWP), as reflected in the published compendia.

Continued in the report…..

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Seasonal Influenza market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Reports

  • The report covers the descriptive overview of Seasonal Influenza, explaining its signs and symptoms, causes, classification, and currently available therapies.
  • Comprehensive insight has been provided into the Seasonal Influenza epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Seasonal Influenza is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Seasonal Influenza market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Seasonal Influenza market.

Report Highlights:

  • The robust pipeline with novel MOA and oral ROA will positively drive the Seasonal Influenza market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Seasonal Influenza R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition and underlying cause.
  • Major players are involved in developing therapies for Seasonal influenza. The launch of emerging therapies will significantly impact the Seasonal Influenza market.
  • Our in-depth analysis of the pipeline assets across different stages of development, different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Seasonal Influenza Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Seasonal Influenza Pipeline Analysis
  • Seasonal Influenza Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Seasonal Influenza Report Key Strengths

  • 11-Years Forecast
  • 7MM Coverage
  • Seasonal Influenza Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Seasonal Influenza Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Seasonal Influenza market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Seasonal Influenza total market size as well as market size by therapies across the 7MM during the forecast period (2022-2032)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Seasonal Influenza market size during the forecast period (2022-2032)?
  • At what CAGR, the Seasonal Influenza market is expected to grow at the 7MM level during the forecast period (2022-2032)?
  • What would be the Seasonal Influenza market outlook across the 7MM during the forecast period (2022-2032)?
  • What would be the Seasonal Influenza market growth till 2032 and what will be the resultant market size in the year 2032?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden, and unmet needs of Seasonal Influenza?
  • What is the historical Seasonal Influenza patient population in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient population of Seasonal Influenza at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Seasonal Influenza?
  • Out of the above-mentioned countries, which country would have the highest cases of Seasonal Influenza during the forecast period (2022-2032)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2022-2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Seasonal Influenza along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Seasonal Influenza in the US, Europe, And Japan?
  • What are the Seasonal Influenza marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Seasonal Influenza?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Seasonal Influenza?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Seasonal Influenza therapies?
  • What are the recent therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Seasonal Influenza and their status?
  • What are the key designations that have been granted for the emerging therapies for Seasonal Influenza?
  • What are the 7MM historical and forecasted market of Seasonal Influenza?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Seasonal Influenza.
  • To understand the future market competition in the Seasonal Influenza market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Seasonal Influenza in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Seasonal Influenza market.
  • To understand the future market competition in the Seasonal Influenza market.

Table of Contents

1. Key Insights

2. Report Introduction

3. Seasonal Influenza Market Overview at a Glance

  • 3.1. Market Share (%) Distribution of Seasonal Influenza in 2019
  • 3.2. Market Share (%) Distribution of Seasonal Influenza in 2032

4. Seasonal Influenza Market: Future Perspective

5. Executive Summary of Seasonal Influenza

6. Key Events

7. Disease Background and Overview: Seasonal Influenza

  • 7.1. Introduction
  • 7.2. Structure Influenza Virus
  • 7.3. Types of Influenza virus
  • 7.4. Key Endpoints in Influenza A
  • 7.5. Inter-species Transmission
  • 7.6. Causes
  • 7.7. Clinical Manifestations and Complications Associated With Influenza
  • 7.8. Pathophysiology
  • 7.9. Diagnosis
    • 7.9.1. Diagnostic Algorithm
    • 7.9.2. Diagnostic Guidelines
  • 7.10. Treatment and Management of Seasonal Influenza
    • 7.10.1. Treatment algorithm for seasonal influenza
    • 7.10.2. Treatment Guidelines

8. Epidemiology and Patient Population

  • 8.1. Key Findings
  • 8.2. Methodology of Epidemiology
  • 8.3. Assumptions and Rationale: 7MM
  • 8.4. Total Medical Visits Related to Seasonal Influenza in the 7MM
  • 8.5. Total Hospitalized Cases of Seasonal Influenza in the 7MM
  • 8.6. The United States
    • 8.6.1. Total Medical visits related to Seasonal Influenza in the United States
    • 8.6.2. Total Hospitalized Cases of Seasonal Influenza in the United States
    • 8.6.3. Type-specific Cases of Seasonal Influenza in the United States
    • 8.6.4. Influenza Vaccination Coverage in the United States
  • 8.7. Major Five European Countries
    • 8.7.1. Germany
      • 8.7.1.1. Total Medical visits related to Seasonal Influenza in Germany
      • 8.7.1.2. Total Hospitalized Cases of Seasonal Influenza in Germany
      • 8.7.1.3. Type-specific Cases of Seasonal Influenza in Germany
      • 8.7.1.4. Influenza Vaccination Coverage in Germany
    • 8.7.2. France
      • 8.7.2.1. Total Medical visits related to Seasonal Influenza in France
      • 8.7.2.2. Total Hospitalized Cases of Seasonal Influenza in France
      • 8.7.2.3. Type-specific Cases of Seasonal Influenza in France
      • 8.7.2.4. Influenza Vaccination Coverage in France
    • 8.7.3. Italy
      • 8.7.3.1. Total Medical visits related to Seasonal Influenza in Italy
      • 8.7.3.2. Total Hospitalized Cases of Seasonal Influenza in Italy
      • 8.7.3.3. Type-specific Cases of Seasonal Influenza in Italy
      • 8.7.3.4. Influenza Vaccination Coverage in Italy
    • 8.7.4. Spain
      • 8.7.4.1. Total Medical visits related to Seasonal Influenza in Spain
      • 8.7.4.2. Total Hospitalized Cases of Seasonal Influenza in Spain
      • 8.7.4.3. Type-specific Cases of Seasonal Influenza in Spain
      • 8.7.4.4. Influenza Vaccination Coverage in Spain
    • 8.7.5. The United Kingdom
      • 8.7.5.1. Total Medical visits related to Seasonal Influenza in the UK
      • 8.7.5.2. Total Hospitalized Cases of Seasonal Influenza in the UK
      • 8.7.5.3. Type-specific Cases of Seasonal Influenza in the UK
      • 8.7.5.4. Influenza Vaccination Coverage in the UK
  • 8.8. Japan
    • 8.8.1. Total Medical Visits related to Seasonal Influenza in Japan
    • 8.8.2. Total Hospitalized Cases of Seasonal Influenza in Japan
    • 8.8.3. Type-specific Cases of Seasonal Influenza in Japan
    • 8.8.4. Influenza Vaccination Coverage in Japan

9. Patient Journey

10. Marketed Drugs

  • 10.1. XOFLUZA (baloxavir marboxil): Genentech/Roche
    • 10.1.1. Product description
    • 10.1.2. Regulatory milestones
    • 10.1.3. Other developmental activities
    • 10.1.4. Clinical development
    • 10.1.5. Clinical trials information
    • 10.1.6. Safety and efficacy
    • 10.1.7. Product profile
  • 10.2. RAPIVAB (peramivir injection): BioCryst Pharmaceuticals
    • 10.2.1. Product description
    • 10.2.2. Regulatory Milestones
    • 10.2.3. Other developmental activities
    • 10.2.4. Clinical development
    • 10.2.5. Clinical trials information
    • 10.2.6. Safety and efficacy
    • 10.2.7. Product profile

11. Marketed Vaccines

  • 11.1. FLUZONE QUADRIVALENT /VAXIGRIP TETRA: Sanofi
    • 11.1.1. Product description
    • 11.1.2. Regulatory milestones
    • 11.1.3. Clinical development
    • 11.1.4. Clinical trials information
    • 11.1.5. Safety and efficacy
    • 11.1.6. Product profile
  • 11.2. FLUZONE High-dose Quadrivalent/ EFLUELDA: Sanofi
    • 11.2.1. Product description
    • 11.2.2. Regulatory milestones
    • 11.2.3. Other developmental activities
    • 11.2.4. Clinical development
    • 11.2.5. Clinical trials information
    • 11.2.6. Safety and efficacy
    • 11.2.7. Product profile
  • 11.3. FLUBLOK QUADRIVALENT/ SUPEMTEK: Sanofi
    • 11.3.1. Product description
    • 11.3.2. Regulatory milestones
    • 11.3.3. Clinical trials information
    • 11.3.4. Safety and efficacy
    • 11.3.5. Product profile
  • 11.4. FLUAD QUADRIVALENT/ FLUAD TETRA: Seqirus
    • 11.4.1. Product description
    • 11.4.2. Regulatory milestones
    • 11.4.3. Clinical development
    • 11.4.4. Clinical trials information
    • 11.4.5. Safety and efficacy
    • 11.4.6. Product profile
  • 11.5. FLUMIST QUADRIVALENT/ FLUENZ TETRA: AstraZeneca
    • 11.5.1. Product description
    • 11.5.2. Regulatory milestones
    • 11.5.3. Clinical development
    • 11.5.4. Clinical trials information
    • 11.5.5. Safety and efficacy
    • 11.5.6. Product profile
  • 11.6. FLUCELVAX QUADRIVALENT/ FLUCELVAX TETRA: Seqirus
    • 11.6.1. Product description
    • 11.6.2. Regulatory milestones
    • 11.6.3. Clinical development
    • 11.6.4. Clinical trials information
    • 11.6.5. Safety and efficacy
    • 11.6.6. Product profile
  • 11.7. AFLURIA QUADRIVALENT: Seqirus
    • 11.7.1. Product description
    • 11.7.2. Regulatory milestones
    • 11.7.3. Clinical development
    • 11.7.4. Clinical trials information
    • 11.7.5. Safety and efficacy
    • 11.7.6. Product profile
  • 11.8. FLUARIX QUADRIVALENT/ FLUARIX TETRA: GSK
    • 11.8.1. Product description
    • 11.8.2. Regulatory milestone
    • 11.8.3. Other developmental activities
    • 11.8.4. Clinical development
    • 11.8.5. Clinical trials information
    • 11.8.6. Safety and efficacy
    • 11.8.7. Product profile
  • 11.9. FLULAVAL QUADRIVALENT: GSK
    • 11.9.1. Product description
    • 11.9.2. Regulatory milestone
    • 11.9.3. Other developmental activities
    • 11.9.4. Clinical development
    • 11.9.5. Clinical trials information
    • 11.9.6. Safety and efficacy
    • 11.9.7. Product profile
  • 11.10. AUDENZ: Seqirus
    • 11.10.1. Product description
    • 11.10.2. Regulatory milestone
    • 11.10.3. Clinical development
    • 11.10.4. Clinical trials information
    • 11.10.5. Safety and efficacy
    • 11.10.6. Product profile
  • 11.11. Pandemic Influenza Vaccine H5N1: AstraZeneca
    • 11.11.1. Product description
    • 11.11.2. Regulatory milestone
    • 11.11.3. Safety and efficacy
    • 11.11.4. Product profile

12. Comparative Analysis

  • 12.1. Total products by phase
  • 12.2. Therapeutic assessment: Active products
    • 12.2.1. Assessment by molecule type
    • 12.2.2. Assessment by stage and molecule type
    • 12.2.3. Assessment by route of administration
    • 12.2.4. Assessment by stage and route of administration

13. Emerging Therapies

  • 13.1. Key Cross Competition
  • 13.2. SAB-176: SAb Biotherapeutics, Inc.
    • 13.2.1. Drug description
    • 13.2.2. Other development activities
    • 13.2.3. Clinical development
    • 13.2.4. Clinical trials information
    • 13.2.5. Safety and efficacy
    • 13.2.6. Product profile
    • 13.2.7. Analysts' views
  • 13.3. Norketotifen: Emergo Therapeutics, Inc.
    • 13.3.1. Product description
    • 13.3.2. Other developmental activities
    • 13.3.3. Clinical development
    • 13.3.4. Clinical trials information
    • 13.3.5. Safety and efficacy
    • 13.3.6. Product profile
  • 13.4. ALVR106: AlloVir
    • 13.4.1. Product description
    • 13.4.2. Other developmental activities
    • 13.4.3. Clinical development
    • 13.4.4. Clinical trials information
    • 13.4.5. Safety and efficacy
    • 13.4.6. Product profile
    • 13.4.7. Analyst views
  • 13.5. CC-42344: Cocrystal Pharma
    • 13.5.1. Product description
    • 13.5.2. Other developmental activities
    • 13.5.3. Clinical development
    • 13.5.4. Clinical trials information
    • 13.5.5. Safety and efficacy
    • 13.5.6. Product profile
    • 13.5.7. Analyst views
  • 13.6. POLB 001: Poolbeg Pharma
    • 13.6.1. Product description
    • 13.6.2. Other developmental activities
    • 13.6.3. Clinical development
    • 13.6.4. Product profile
    • 13.6.5. Analyst views
  • 13.7. LAGEVRIO: Ridgeback Biotherapeutics
    • 13.7.1. Product description
    • 13.7.2. Other developmental activities
    • 13.7.3. Preclinical development
    • 13.7.4. Safety and efficacy
    • 13.7.5. Product profile
    • 13.7.6. Analyst views
  • 13.8. AV5124: Viriom, Inc.
    • 13.8.1. Product description
    • 13.8.2. Clinical development
    • 13.8.3. Safety and efficacy
    • 13.8.4. Product profile
    • 13.8.5. Analyst views
  • 13.9. FluCide (Injectable): NanoViricides
    • 13.9.1. Product description
    • 13.9.2. Safety and efficacy
    • 13.9.3. Product profile
    • 13.9.4. Analyst views
  • 13.10. FluCide (Oral): NanoViricides
    • 13.10.1. Product description
    • 13.10.2. Safety and efficacy
    • 13.10.3. Product profile
    • 13.10.4. Analyst views
  • 13.11. Research Program: Sirtuin Targeted Therapeutics for Respiratory Viral Infections: Evrys Bio
    • 13.11.1. Product description
    • 13.11.2. Product profile
    • 13.11.3. Analyst views
  • 13.12. ETH 47: ETHRIS
    • 13.12.1. Product description
    • 13.12.2. Other developmental activities
    • 13.12.3. Product profile
    • 13.12.4. Analyst views
  • 13.13. Research Program: Anti-RNA Virus Therapeutics: Kino Pharma
    • 13.13.1. Product description
    • 13.13.2. Product profi le
    • 13.13.3. Analyst views

14. Emerging Vaccines and Prophylactic Agents

  • 14.1. Key Cross Competition
  • 14.2. mRNA-1010: ModernaTX, Inc.
    • 14.2.1. Drug description
    • 14.2.2. Other development activities
    • 14.2.3. Clinical development
    • 14.2.4. Clinical trials information
    • 14.2.5. Safety and efficacy
    • 14.2.6. Product profile
    • 14.2.7. Analysts' views
  • 14.3. NanoFlu: Novavax
    • 14.3.1. Drug description
    • 14.3.2. Other development activities
    • 14.3.3. Clinical development
    • 14.3.4. Clinical trials information
    • 14.3.5. Safety and efficacy
    • 14.3.6. Product profile
    • 14.3.7. Analysts' views
  • 14.4. Quadrivalent VLP vaccine: Medicago
    • 14.4.1. Product description
    • 14.4.2. Other developmental activities
    • 14.4.3. Clinical development
    • 14.4.4. Clinical trials information
    • 14.4.5. Safety and efficacy
    • 14.4.6. Product profile
    • 14.4.7. Analysts' views
  • 14.5. aQIV: Seqirus
    • 14.5.1. Product description
    • 14.5.2. Other developmental activities
    • 14.5.3. Clinical development
    • 14.5.4. Clinical trials information
    • 14.5.5. Product profile
  • 14.6. VXA-A1.1: Vaxart
    • 14.6.1. Product description
    • 14.6.2. Other developmental activities
    • 14.6.3. Clinical development
    • 14.6.4. Clinical trials information
    • 14.6.5. Safety and efficacy
    • 14.6.6. Product profile
    • 14.6.7. Analysts' views
  • 14.8. FLU-v: Imutex/ PepTcell Limited
    • 14.8.1. Product description
    • 14.8.2. Other developmental activities
    • 14.8.3. Clinical development
    • 14.8.4. Clinical trials information
    • 14.8.5. Safety and efficacy
    • 14.8.6. Product profile
    • 14.8.7. Analysts' views
  • 14.9. VIS410: Otsuka Pharmaceutical Co., Ltd. / Visterra, Inc.
    • 14.9.1. Product description
    • 14.9.2. Other developmental activities
    • 14.9.3. Clinical development
    • 14.9.4. Clinical trials information
    • 14.9.5. Safety and efficacy
    • 14.9.6. Product profile
  • 14.10. INNA-051: ENA Respiratory Pty Ltd
    • 14.10.1. Product description
    • 14.10.2. Other developmental activities
    • 14.10.3. Clinical development
    • 14.10.4. Clinical trials information
    • 14.10.5. Product profile
  • 14.11. Neumifil: Pneumagen Ltd.
    • 14.11.1. Product description
    • 14.11.2. Other developmental activities
    • 14.11.3. Clinical development
    • 14.11.4. Clinical trials information
    • 14.11.5. Safety and efficacy
    • 14.11.6. Product profile
  • 14.12. CD388: Cidara Therapeutics
    • 14.12.1. Product profile
    • 14.12.2. Other developmental activities
    • 14.12.3. Clinical development
    • 14.12.4. Clinical trials information
    • 14.12.5. Product profile
  • 14.13. mRNA 1030: Moderna Therapeutics
    • 14.13.1. Product description
    • 14.13.2. Other developmental activities
    • 14.13.3. Clinical development
    • 14.13.4. Clinical trials information
    • 14.13.5. Product profile
    • 14.13.6. Analyst views
  • 14.14. Adjuvanted Seasonal Recombinant QVLP Influenza Vaccine: Medicago
    • 14.14.1. Product description
    • 14.14.2. Clinical development
    • 14.14.3. Clinical trials information
    • 14.14.4. Product profile
    • 14.14.5. Analyst views
  • 14.15. SP0273: Sanofi
    • 14.15.1. Product description
    • 14.15.2. Other developmental activities
    • 14.15.3. Clinical development
    • 14.15.4. Clinical trials information
    • 14.15.5. Product profile
    • 14.15.6. Analyst views
  • 14.16. UniFlu: Emergent BioSolutions
    • 14.16.1. Product description
    • 14.16.2. Other developmental activities
    • 14.16.3. Clinical development
    • 14.16.4. Clinical trials information
    • 14.16.5. Product profile
    • 14.16.6. Analyst views
  • 14.17. GSK4382276A: GlaxoSmithKline
    • 14.17.1. Product description
    • 14.17.2. Other developmental activities
    • 14.17.3. Clinical development
    • 14.17.4. Clinical trials information
    • 14.17.5. Product profile
    • 14.17.6. Analyst views
  • 14.18. CVSQIV: CureVac
    • 14.18.1. Product description
    • 14.18.2. Other developmental activities
    • 14.18.3. Clinical development
    • 14.18.4. Clinical trials information
    • 14.18.5. Product profile
    • 14.18.6. Analyst views
  • 14.19. CodaVax: Codagenix
    • 14.19.1. Product description
    • 14.19.2. Other developmental activities
    • 14.19.3. Clinical development
    • 14.19.4. Clinical trials information
    • 14.19.5. Product profile
    • 14.19.6. Analyst views
  • 14.20. MT-2654: Mitsubishi Tanabe Pharma Corporation
    • 14.20.1. Product description
    • 14.20.2. Product profile
    • 14.20.3. Analyst views
  • 14.21. BWV-101: Blue Water Vaccines
    • 14.21.1. Product description
    • 14.21.2. Other developmental activities
    • 14.21.3. Preclinical development
    • 14.21.4. Safety and efficacy
    • 14.21.5. Product profile
    • 14.21.6. Analyst views
  • 14.22. Recombinant Universal Influenza Vaccine: TFF Pharmaceuticals
    • 14.22.1. Product description
    • 14.22.2. Other developmental activities
    • 14.22.3. Preclinical development
    • 14.22.4. Safety and efficacy
    • 14.22.5. Product profile
    • 14.22.6. Analyst views
  • 14.23. VT-105: Versatope Therapeutics
    • 14.23.1. Product description
    • 14.23.2. Other developmental activities
    • 14.23.3. Product profile
    • 14.23.4. Analyst views
  • 14.24. AVA2300: Avalia Immunotherapies
    • 14.24.1. Product description
    • 14.24.2. Product profile
    • 14.24.3. Analyst views
  • 14.25. Seasonal Influenza Vaccine: Dyadic International Inc.
    • 14.25.1. Product description
    • 14.25.2. Product profile
    • 14.25.3. Analyst views
  • 14.26. Universal Influenza Vaccine: Vaxine Pty Ltd.
    • 14.26.1. Product description
    • 14.26.2. Other developmental activities
    • 14.26.3. Safety and efficacy
    • 14.26.4. Product profile
    • 14.26.5. Analyst views
  • 14.27. LHNVD-105: Longhorn Vaccines & Diagnostics LLC
    • 14.27.1. Product description
    • 14.27.2. Safety and efficacy
    • 14.27.3. Product profile
    • 14.27.4. Analyst views
  • 14.28. PDS0202: PDS Biotechnology
    • 14.28.1. Product description
    • 14.28.2. Other developmental activities
    • 14.28.3. Safety and efficacy
    • 14.28.4. Product profile
    • 14.28.5. Analyst views
  • 14.29. Universal flu vaccine: EpiVax
    • 14.29.1. Product description
    • 14.29.2. Other developmental activities
    • 14.29.3. Product profile
    • 14.29.4. Analyst views
  • 14.30. Seasonal flu vaccine (naNO-Flu): Emergex Vaccines
    • 14.30.1. Product description
    • 14.30.2. Other developmental activities
    • 14.30.3. Product profile
    • 14.30.4. Analyst views
  • 14.31. Seasonal Influenza Quadrivalent Vaccine: Vaxart
    • 14.31.1. Product description
    • 14.31.2. Product profile
    • 14.31.3. Analyst views
  • 14.32. LUNAR-FLU: Arcturus Therapeutics
    • 14.32.1. Product description
    • 14.32.2. Product profile
    • 14.32.3. Analyst views
  • 14.33. Seasonal Tetravalent Influenza VLP Vaccine: TechnoVax
    • 14.33.1. Product description
    • 14.33.2. Product profile
    • 14.33.3. Analyst views
  • 14.34. Universal Influenza Vaccine: TechnoVax
    • 14.34.1. Product description
    • 14.34.2. Other developmental activities
    • 14.34.3. Product profile
    • 14.34.4. Analyst views
  • 14.35. GammaFlu: Gamma Vaccines Pty Ltd
    • 14.35.1. Product description
    • 14.35.2. Product profile
    • 14.35.3. Analyst views
  • 14.36. OraPro-Flu: iosBio
    • 14.36.1. Product description
    • 14.36.2. Product profile
    • 14.36.3. Analyst views
  • 14.37. CR9114: Leyden Labs
    • 14.37.1. Product description
    • 14.37.2. Other developmental activities
    • 14.37.3. Product profile
    • 14.37.4. Analyst views
  • 14.38. Monoclonal Antibodies (mAbs) Combination: Invivyd, Inc.
    • 14.38.1. Product description
    • 14.38.2. Other developmental activities
    • 14.38.3. Product profile
    • 14.38.4. Analyst views
  • 14.39. Universal Influenza Virus Vaccine: Najit Technologies
    • 14.39.1. Product description
    • 14.39.2. Other developmental activities
    • 14.39.3. Product profile
    • 14.39.4. Analyst views
  • 14.40. Universal Influenza Vaccine: iQur
    • 14.40.1. Product description
    • 14.40.2. Other developmental activities
    • 14.40.3. Preclinical development
    • 14.40.4. Safety and efficacy
    • 14.40.5. Product profile
    • 14.40.6. Analyst views
  • 14.41. CAL-200: Calder Biosciences, Inc.
    • 14.41.1. Product description
    • 14.41.2. Other developmental activities
    • 14.41.3. Product profile
    • 14.41.4. Analyst views
  • 14.42. Adjuvanted Vaccines for Seasonal Influenza: Dynavax
    • 14.42.1. Product description
    • 14.42.2. Other developmental activities
    • 14.42.3. Product profile
    • 14.42.4. Analyst views
  • 14.43. Quadrivalent Flu Vaccine: Icosavax
    • 14.43.1. Product description
    • 14.43.2. Product profile
    • 14.43.3. Analyst views
  • 14.44. UMN-101: UMN Pharma
    • 14.44.1. Product description
    • 14.44.2. Product profile
    • 14.44.3. Analyst views
  • 14.45. Quadrivalent Seasonal Influenza Vaccine: Clover Biopharmaceuticals
    • 14.45.1. Product description
    • 14.45.2. Product profile
    • 14.45.3. Analyst views

15 Seasonal Influenza: Seven Major Market Analysis

  • 15.1. Key Findings
  • 15.2. Market Methodology
  • 15.3. Market Outlook
  • 15.4. Potential of Emerging Therapies
  • 15.5. Key Market Forecast Assumptions
  • 15.6. Market Size of Seasonal Influenza in the 7MM
  • 15.7. Market Size of Seasonal Influenza by products (treatment and prophylaxis) in the 7MM
  • 15.8. The United States Market Size
    • 15.8.1. Total Market Size of Seasonal Influenza
    • 15.8.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)
  • 15.9. Market Size of Seasonal Influenza in the EU-5
    • 15.9.1. Germany
      • 15.9.1.1. Total Market Size of Seasonal Influenza
      • 15.9.1.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)
    • 15.9.2. France
      • 15.9.2.1. Total Market Size of Seasonal Influenza
      • 15.9.2.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)
    • 15.9.3. Italy
      • 15.9.3.1. Total Market Size of Seasonal Influenza
      • 15.9.3.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)
    • 15.9.4. Spain
      • 15.9.4.1. Total Market Size of Seasonal Influenza
      • 15.9.4.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)
    • 15.9.5. The United Kingdom
      • 15.9.5.1. Total Market Size of Seasonal Influenza
      • 15.9.5.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)
  • 15.10. Japan Market Size
    • 15.10.1. Total Market Size of Seasonal Influenza
    • 15.10.2. Market Size of Seasonal Influenza by products (treatment and prophylaxis)

16. Key Opinion Leaders' Views

17. Market Drivers

18. Market Barriers

19. Unmet Needs

20. SWOT Analysis

21. Market Access and Reimbursement

22. Appendix

  • 22.1. Bibliography
  • 22.2. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight